To Review Products For Both Operable and Inoperable Brain Tumors

BETHESDA, Md., June 6, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today announced that its Chief Technical Officer, Dr. Marnix Bosch, will make a presentation at the Brain Tumor Biotech Summit sponsored by the Weill Cornell Medical College and Voices Against Brain Cancer in New York City, New York on Friday, June 7, 2013.

Dr. Bosch will review NW Bio’s non-toxic personalized immune therapies for both operable and inoperable brain tumors, and the clinical trial programs for each of these.

This will include the ongoing 312-patient Phase III international trial of DCVax-L for Glioblastoma multiforme brain cancer, which is currently enrolling patients in both the US and Europe.

It will also include review of the Phase I/II trial of DCVax-Direct, which is expected to be launching soon for all inoperable solid tumors, including tumors that have metastasized to the brain from other locations.

Dr. Bosch will be presenting at the Weill Cornell Medical College’s Uris Auditorium at 8:20 am on Friday, June 7, 2013. The Auditorium is located at 1300 New York Avenue at 69th Street. Dr. Bosch’s presentation will be available on the NW Bio Website starting at 10:00 am on Friday morning June 7, 2013.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company’s lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings.  Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.